Developments of small molecules as inhibitors for carbonic anhydrase isoforms
Emmanuel Ramsey Buabeng1, Maged Henary1
1Department of Chemistry, 100 Piedmont Avenue SE, Georgia State University, Atlanta, GA 30303, USA; Center for Diagnostics and Therapeutics, 100 Piedmont Avenue SE, Georgia State University, Atlanta, GA 30303, USA.
Abstract:
Carbonic anhydrases are ubiquitous, and their role in the hydration of carbon dioxide is essential for the survival of many tissues and organs. However, their association with many pathological diseases, especially in glaucoma, Alzheimer's, obesity, epilepsy, and tumorigenesis, has prompted the design and synthesis of novel carbonic anhydrase inhibitors (CAIs). Herein we describe (1) approaches used in the design of CAIs and (2) synthesis of small molecules as CAIs within the last five years. Despite the active research in this area, there are still more avenues to explore, especially selective inhibition of CA I, CA IX, and XII. These isoforms would continue to open up a diversity of carbonic anhydrase inhibitors containing 1,2,3-triazoles, imidazolone, pyrrolidone, thiadiazole, isatin, and glycoconjugates as part of their molecular frameworks.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Enzyme Inhibition
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
ATP Synthase: Mechanism


